Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27669922 | 0.94 | GNAI3 (0.54) | EPHX1EPHX2CCR1HTR4GNAI3 | |
| SCHEMBL8971499 | 0.84 | PAOX (0.46) | EPHX1EPHX2L3MBTL1LTA4HSMN1; SMN2 | |
| SCHEMBL27348781 | 0.82 | SMN1; SMN2 (0.58) | EPHX1EPHX2L3MBTL1HTR4LTA4H | |
| SCHEMBL27570291 | 0.81 | LTA4H (0.48) | EPHX1EPHX2L3MBTL1HTR4LTA4H | |
| SCHEMBL27517725 | 0.79 | LTA4H (0.53) | HTR4LTA4HMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27688983 | 0.79 | PARP1 (0.49) | EPHX1EPHX2L3MBTL1LTA4HSMN1; SMN2 | |
| SCHEMBL20970613 | 0.78 | EPHX1 (0.59) | EPHX1EPHX2CCR1MEN1KMT2A | |
| SCHEMBL5227695 | 0.77 | SMN1; SMN2 (0.67) | EPHX1EPHX2L3MBTL1GNAI3GNAO1 | |
| SCHEMBL14450366 | 0.77 | EPHX1 (0.51) | EPHX1EPHX2CCR1L3MBTL1HTR4 | |
| SCHEMBL2858477 | 0.77 | LTA4H (0.44) | EPHX1EPHX2L3MBTL1LTA4HMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2015-10-01 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPO, MPO, CAT | EPHX1 2356/4885EPHX2 3007/4885CCR1 2321/4885 |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | LPO, MPO, CAT | EPHX1 2356/4885EPHX2 3007/4885CCR1 2321/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | EPHX1 2356/4885EPHX2 3007/4885CCR1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.